Whole-genome Sequencing Identifies ADGRG6 Enhancer Mutations and FRS2 Duplications As Angiogenesis-Related Drivers in Bladder Cancer

Song Wu,Tong Ou,Nianzeng Xing,Jiang Lu,Shengqing Wan,Changxi Wang,Xi Zhang,Feiya Yang,Yi Huang,Zhiming Cai

DOI: https://doi.org/10.1038/s41467-019-08576-5

IF: 16.6

2019-01-01

Nature Communications

Abstract:Bladder cancer is one of the most common and highly vascularized cancers. To better understand its genomic structure and underlying etiology, we conduct whole-genome and targeted sequencing in urothelial bladder carcinomas (UBCs, the most common type of bladder cancer). Recurrent mutations in noncoding regions affecting gene regulatory elements and structural variations (SVs) leading to gene disruptions are prevalent. Notably, we find recurrent ADGRG6 enhancer mutations and FRS2 duplications which are associated with higher protein expression in the tumor and poor prognosis. Functional assays demonstrate that depletion of ADGRG6 or FRS2 expression in UBC cells compromise their abilities to recruit endothelial cells and induce tube formation. Moreover, pathway assessment reveals recurrent alterations in multiple angiogenesis-related genes. These results illustrate a multidimensional genomic landscape that highlights noncoding mutations and SVs in UBC tumorigenesis, and suggest ADGRG6 and FRS2 as novel pathological angiogenesis regulators that would facilitate vascular-targeted therapies for UBC.